Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Oncodesign’s kinase inhibitor library currently contains over 8,000 macrocycles. These type I kinase inhibitors, profiled using the human kinome, are potent, highly selective, and have good cell penetration. They also have good criteria in terms of developability, physicochemical properties and eADMET, with a highly predictable SAR.
Several leads are currently being optimized, both for known kinases and for unexplored kinases; they will become tomorrow’s targeted therapies in precision medicine.
The probe-based drug discovery approach helps identify « First in Class » opportunities for little explored or unexplored kinases, and our molecular diversity screening approach for kinases of interest paves the way for potential best-in-class next-generation inhibitors..